Answers are grounded in this paper and cite their sources.
Atinvicitinib is a Janus kinase 1-selective-inhibitor approved for the treatment of pruritus associated with allergic dermatitis, including canine atopic dermatitis (cAD). An examiner-masked, randomized study assessed safety and clinical improvement in pruritus and dermatitis severity in dogs with allergic dermatitis following treatment with atinvicitinib (Numelvi ® tablets, MSD Animal Health) or oclacitinib (Apoquel ® chewable tablets, Zoetis). Client-owned dogs ( n = 69) with allergic dermatitis and a pruritus visual analog scale (PVAS) score ≥ 6 were enrolled at nine veterinary clinics in Portugal and Spain and treated with either atinvicitinib (0.8–1.2 mg/kg once daily with food, n = 34) or oclacitinib (0.4–0.6 mg/kg, with or without food, twice daily for 14 days then once daily, n = 35) for 28 (± 1) days. Safety was assessed based on adverse event (AE) reporting. Owners assessed PVAS on day (D) 0, 7, 14, 21 and 28, including overall response to treatment (ORTT-VAS) on D28. Veterinarians performed physical examinations and dermatitis VAS score (DVAS) on D0 and 28. Efficacy was evaluated as the percentage reduction in PVAS and DVAS from baseline. A dynamic longitudinal model was used to compare effectiveness between groups. On D28, 70% atinvicitinib- and 65% oclacitinib-treated dogs had PVAS < 2 (normal). Dynamic longitudinal modelling showed that pruritus reduction after 28 days of atinvicitinib was non-inferior to that with oclacitinib at label doses. There was a 74% reduction in DVAS in both treatments by D28. All of the few AEs observed were consistent with approved product information. Atinvicitinib once daily with food is safe and effective in reducing pruritus and dermatitis severity in dogs with allergic dermatitis.
No takes yet. Share an insight, caveat, or question.
Heinau et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: